Tammela TL - Search Results

1

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, Vuorela A, Nykänen P, Pohjanjousi P, Snapir A, Fizazi K. Massard C, et al. Among authors: tammela tl. Eur Urol. 2016 May;69(5):834-40. doi: 10.1016/j.eururo.2015.09.046. Epub 2015 Oct 17. Eur Urol. 2016. PMID: 26463318 Free article. Clinical Trial.

2

Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.

Kontturi M, Sotarauta M, Tammela T, Lukkarinen O, Romppainen ML, Gröhn P. Kontturi M, et al. Eur Urol. 1988;15(1-2):43-7. doi: 10.1159/000473393. Eur Urol. 1988. PMID: 2975221

3

Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia.

Tammela TL, Kontturi MJ. Tammela TL, et al. J Urol. 1995 Oct;154(4):1466-9. J Urol. 1995. PMID: 7544845 Clinical Trial.

4

Aetiology of priapism in 207 patients.

Kulmala R, Lehtonen T, Nieminen P, Tammela T. Kulmala R, et al. Eur Urol. 1995;28(3):241-5. doi: 10.1159/000475058. Eur Urol. 1995. PMID: 8536779

5

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

6

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. Tyrrell CJ, et al. Eur Urol. 1998;33(5):447-56. doi: 10.1159/000019634. Eur Urol. 1998. PMID: 9643663 Clinical Trial.

7

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: tammela tl. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

8

Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network.

Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, Hakama M, Rannikko S, Tammela TL, Stenman U. Finne P, et al. Among authors: tammela tl. Urology. 2000 Sep 1;56(3):418-22. doi: 10.1016/s0090-4295(00)00672-5. Urology. 2000. PMID: 10962306 Clinical Trial.

9

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.

Finne P, Zhang WM, Auvinen A, Leinonen J, Määttänen L, Rannikko S, Tammela TL, Stenman UH. Finne P, et al. Among authors: tammela tl. J Urol. 2000 Dec;164(6):1956-60. J Urol. 2000. PMID: 11061890

10

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: tammela tl. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

601 results

Search Page